Vc-MMAD is primarily utilized in the development of antibody-drug conjugates (ADCs), which are targeted cancer therapies. It serves as a potent cytotoxic payload that is linked to antibodies designed to recognize specific cancer cell markers. This targeted approach allows Vc-MMAD to deliver its toxic effects directly to cancer cells, minimizing damage to healthy tissues. Its application is crucial in enhancing the precision and efficacy of cancer treatments, particularly in cases where traditional chemotherapy may be less effective or too toxic. Research and clinical trials continue to explore its potential in treating various types of cancers, including solid tumors and hematologic malignancies.